Identification
- Summary
Potassium acetate is a medication used to treat hypokalemia.
- Brand Names
- Hyperlyte, Normosol-M
- Generic Name
- Potassium acetate
- DrugBank Accession Number
- DB14498
- Background
Not Available
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Potassium acetate (DB14498)
- Weight
- Average: 98.1423
Monoisotopic: 97.977011201 - Chemical Formula
- C2H3KO2
- Synonyms
- Potassium acetate
Pharmacology
- Indication
Potassium is used to regulate hypokalemia as a primary condition or secondary to other medical conditions.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Associated Therapies
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
Potassium is the major cation (positive ion) inside animal cells, while sodium is the major cation outside animal cells. The concentration differences of these charged particles causes a difference in electric potential between the inside and outside of cells, known as the membrane potential. The balance between potassium and sodium is maintained by ion pumps in the cell membrane. The cell membrane potential created by potassium and sodium ions allows the cell generate an action potential—a "spike" of electrical discharge. The ability of cells to produce electrical discharge is critical for body functions such as neurotransmission, muscle contraction, and heart function. Potassium is also an essential mineral needed to regulate water balance, blood pressure and levels of acidity.
Target Actions Organism USodium/potassium-transporting ATPase subunit alpha-1 Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Mostly urine but also skin and feces.
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Abacavir may decrease the excretion rate of Potassium acetate which could result in a higher serum level. Acebutolol Potassium acetate may increase the hyperkalemic activities of Acebutolol. Aceclofenac Potassium acetate may increase the hyperkalemic activities of Aceclofenac. Acemetacin Potassium acetate may increase the hyperkalemic activities of Acemetacin. Acetaminophen Acetaminophen may decrease the excretion rate of Potassium acetate which could result in a higher serum level. Acetazolamide Acetazolamide may increase the excretion rate of Potassium acetate which could result in a lower serum level and potentially a reduction in efficacy. Acetylsalicylic acid Potassium acetate may increase the hyperkalemic activities of Acetylsalicylic acid. Aclidinium Aclidinium may decrease the excretion rate of Potassium acetate which could result in a higher serum level. Acrivastine Acrivastine may decrease the excretion rate of Potassium acetate which could result in a higher serum level. Acyclovir Acyclovir may decrease the excretion rate of Potassium acetate which could result in a higher serum level. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Active Moieties
Name Kind UNII CAS InChI Key Potassium cation ionic 295O53K152 24203-36-9 NPYPAHLBTDXSSS-UHFFFAOYSA-N - Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Potassium Acetate Injection, solution, concentrate 392 mg/1mL Intravenous American Regent 1990-09-30 2014-07-01 US 
Potassium Acetate Liquid 392 mg / mL Intravenous Sandoz Canada Incorporated 1988-12-31 2016-10-24 Canada 
Potassium Acetate Injection, solution, concentrate 3.93 g/20mL Intravenous Hospira, Inc. 2014-03-27 Not applicable US Potassium Acetate Injection, solution 196 mg/1mL Intravenous American Regent 1990-09-30 2012-11-29 US Potassium Acetate Injection, solution, concentrate 196.3 mg/1mL Intravenous Hospira, Inc. 2013-12-23 Not applicable US Potassium Acetate Inj 2meq/ml Solution 2 mEq / mL Intravenous Abbott 1984-12-31 2008-06-06 Canada Potassium Acetate Inj 392mg/ml USP Liquid 392 mg / mL Intravenous Lyphomed, Division Of Fujisawa Canada Inc. 1984-12-31 1996-09-10 Canada Potassium Acetate Injection Solution 392 mg / mL Intravenous Fresenius Kabi 1984-12-31 Not applicable Canada Potassium Acetate Injection USP Liquid 39.2 % w/v Intravenous Omega Laboratories Ltd 2016-07-18 Not applicable Canada - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Potassium Acetate Injection 200 meq/100mL Intravenous Exela Pharma Sciences, LLC 2023-08-01 Not applicable US Potassium Acetate Injection, solution, concentrate 3.93 g/20mL Intravenous Exela Pharma Sciences, LLC 2016-01-07 Not applicable US Potassium Acetate Injection 100 meq/50mL Intravenous Exela Pharma Sciences, LLC 2023-08-01 Not applicable US - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image DBL POTASSIUM ACETATE CONCENTRATED INJECTION 2.45 g/5 ml Injection 2.45 g/5ml Intravenous PFIZER PRIVATE LIMITED 1991-05-21 Not applicable Singapore 
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Aminoplasmal B. Braun 10%E Solution for Intravenous Infusion Potassium acetate (2.453 g/1000ml) + Alanine (10.5 g/1000ml) + Arginine (11.5 g/1000ml) + Aspartic acid (5.6 g/1000ml) + Glutamic acid (7.2 g/1000ml) + Glycine (12 g/1000ml) + Histidine (3 g/1000ml) + Isoleucine (5 g/1000ml) + Leucine (8.9 g/1000ml) + Lysine hydrochloride (8.56 g/1000ml) + Magnesium chloride hexahydrate (0.508 g/1000ml) + Methionine (4.4 g/1000ml) + Phenylalanine (4.7 g/1000ml) + Proline (5.5 g/1000ml) + Serine (2.3 g/1000ml) + Sodium acetate trihydrate (2.858 g/1000ml) + Sodium hydroxide (0.36 g/1000ml) + Sodium phosphate, dibasic dodecahydrate (3.581 g/1000ml) + Threonine (4.2 g/1000ml) + Tryptophan (1.6 g/1000ml) + Tyrosine (0.4 g/1000ml) + Valine (6.2 g/1000ml) Injection, solution Intravenous B.BRAUN MEDICAL INDUSTRIES SDN BHD 2020-09-08 Not applicable Malaysia 
AMINOPLASMAL B.BRAUN 10% E SOLUTION FOR INFUSION Potassium acetate (2.453 g/1000ml) + Alanine (10.50 g/1000ml) + Arginine (11.50 g/1000ml) + Aspartic acid (5.60 g/1000ml) + Glutamic acid (7.20 g/1000ml) + Glycine (12.00 g/1000ml) + Histidine (3.00 g/1000ml) + Isoleucine (5.00 g/1000ml) + Leucine (8.90 g/1000ml) + Lysine hydrochloride (8.56 g/1000ml) + Magnesium chloride hexahydrate (0.508 g/1000ml) + Methionine (4.40 g/1000ml) + Phenylalanine (4.70 g/1000ml) + Proline (5.50 g/1000ml) + Serine (2.30 g/1000ml) + Sodium acetate trihydrate (2.858 g/1000ml) + Sodium hydroxide (0.360 g/1000ml) + Sodium phosphate, dibasic dodecahydrate (3.581 g/1000ml) + Threonine (4.20 g/1000ml) + Tryptophan (1.60 g/1000ml) + Tyrosine (0.40 g/1000ml) + Valine (6.20 g/1000ml) Solution Intravenous B. BRAUN SINGAPORE PTE LTD 2018-01-23 Not applicable Singapore AMINOPLASMAL-10% E INFUSION Potassium acetate (2.45 g/l) + Acetylcysteine (0.5 g/l) + Alanine (13.7 g/l) + Arginine (9.2 g/l) + Asparagine (3.27 g/l) + Aspartic acid (1.3 g/l) + Glutamic acid (4.6 g/l) + Glycine (7.9 g/l) + Histidine (5.2 g/l) + Isoleucine (5.1 g/l) + Leucine (8.9 g/l) + Lysine hydrochloride (5.6 g/l) + Magnesium acetate (0.56 g/l) + Malic acid (1.01 g/l) + Methionine (3.8 g/l) + N-acetyltyrosine (1 g/l) + Ornithine hydrochloride (2.51 g/l) + Phenylalanine (5.1 g/l) + Proline (8.9 g/l) + Serine (2.4 g/l) + Sodium acetate (3.95 g/l) + Sodium hydroxide (0.2 g/l) + Sodium phosphate, monobasic (1.4 g/l) + Threonine (4.1 g/l) + Tryptophan (1.8 g/l) + Tyrosine (0.3 g/l) + Valine (4.8 g/l) Injection Intravenous B. BRAUN SINGAPORE PTE LTD 1991-05-13 Not applicable Singapore AMINOPLASMAL-5% E INFUSION Potassium acetate (2.45 g/1000ml) + Acetylcysteine (0.25 g/1000ml) + Alanine (6.85 g/1000ml) + Arginine (4.6 g/1000ml) + Asparagine (1.64 g/1000ml) + Aspartic acid (0.65 g/1000ml) + Glutamic acid (2.3 g/1000ml) + Glycine (3.95 g/1000ml) + Histidine (2.6 g/1000ml) + Isoleucine (2.55 g/1000ml) + Leucine (4.45 g/1000ml) + Lysine hydrochloride (2.8 g/1000ml) + Magnesium acetate (0.56 g/1000ml) + Malic acid (1.01 g/1000ml) + Methionine (1.9 g/1000ml) + N-acetyltyrosine (0.35 g/1000ml) + Ornithine hydrochloride (1.25 g/1000ml) + Phenylalanine (2.55 g/1000ml) + Proline (4.45 g/1000ml) + Serine (1.2 g/1000ml) + Sodium acetate (3.95 g/1000ml) + Sodium hydroxide (0.2 g/1000ml) + Sodium phosphate, monobasic (1.4 g/1000ml) + Threonine (2.05 g/1000ml) + Tryptophan (0.9 g/1000ml) + Tyrosine (0.3 g/1000ml) + Valine (2.4 g/1000ml) Injection Intravenous B. BRAUN SINGAPORE PTE LTD 1991-05-13 Not applicable Singapore AMINOPLASMAL® 10% E Potassium acetate (2.453 g) + Alanine (10.5 g) + Arginine (11.5 g) + Aspartic acid (5.6 g) + Glutamic acid (7.2 g) + Glycine (12 g) + Histidine (3 g) + Isoleucine (5 g) + Leucine (8.9 g) + Lysine hydrochloride (8.56 g) + Magnesium chloride hexahydrate (0.508 g) + Phenylalanine (4.7 g) + Proline (5.5 g) + Racemethionine (4.4 g) + Serine (2.3 g) + Sodium acetate trihydrate (2.858 g) + Sodium hydroxide (0.36 g) + Sodium phosphate, dibasic dodecahydrate (3.581 g) + Threonine (4.2 g) + Tryptophan (1.6 g) + Tyrosine (0.4 g) + Valine (6.2 g) Solution Intravenous B. BRAUN MEDICAL S.A. 2015-07-27 Not applicable Colombia 
Aminosyn Potassium acetate (128 mg/100mL) + Alanine (448 mg/100mL) + Arginine (343 mg/100mL) + Glycine (448 mg/100mL) + Histidine (105 mg/100mL) + Isoleucine (252 mg/100mL) + Leucine (329 mg/100mL) + Lysine acetate (252 mg/100mL) + Magnesium acetate (21 mg/100mL) + Methionine (140 mg/100mL) + Phenylalanine (154 mg/100mL) + Phosphoric acid (40 mg/100mL) + Proline (300 mg/100mL) + Serine (147 mg/100mL) + Sodium chloride (234 mg/100mL) + Threonine (182 mg/100mL) + Tryptophan (56 mg/100mL) + Tyrosine (31 mg/100mL) + Valine (280 mg/100mL) Injection, solution Intravenous Hospira, Inc. 2011-03-23 2017-11-01 US Aminosyn 3.5% M Potassium acetate (128 mg / 100 mL) + Alanine (448 mg / 100 mL) + Arginine (343 mg / 100 mL) + Glycine (448 mg / 100 mL) + Histidine (105 mg / 100 mL) + Isoleucine (252 mg / 100 mL) + Leucine (329 mg / 100 mL) + Lysine acetate (252 mg / 100 mL) + Magnesium acetate (21 mg / 100 mL) + Methionine (140 mg / 100 mL) + Phenylalanine (154 mg / 100 mL) + Proline (300 mg / 100 mL) + Serine (147 mg / 100 mL) + Sodium chloride (234 mg / 100 mL) + Threonine (182 mg / 100 mL) + Tryptophan (56 mg / 100 mL) + Tyrosine (31 mg / 100 mL) + Valine (280 mg / 100 mL) Liquid Intravenous Abbott 1980-12-31 1999-08-09 Canada Hyperlyte (multi-electrolyte Concentrate) Potassium acetate (690 mg / 25 mL) + Calcium acetate (440 mg / 25 mL) + Sodium gluconate (1.09 g / 25 mL) + Magnesium acetate (860 mg / 25 mL) + Potassium chloride (2.46 g / 25 mL) + Sodium acetate (2.72 g / 25 mL) Liquid Intravenous B. Braun Medical Inc. 1998-09-04 2017-07-15 Canada Hyperlyte CR Multi-electrolyte Concentrate Potassium acetate (1.96 g / 20 mL) + Calcium chloride (370 mg / 20 mL) + Magnesium chloride (510 mg / 20 mL) + Sodium acetate (680 mg / 20 mL) + Sodium chloride (1.17 g / 20 mL) Liquid Intravenous B. Braun Medical Inc. 1998-09-03 2021-08-19 Canada Lypholyte Potassium acetate (690 mg / 20 mL) + Calcium acetate (440 mg / 20 mL) + Sodium gluconate (1.1 g / 20 mL) + Magnesium acetate (860 mg / 20 mL) + Potassium chloride (2.5 g / 20 mL) + Sodium acetate (2.7 g / 20 mL) Solution Intravenous Partners Health Care, Inc. 1996-08-14 2008-01-10 Canada - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Hyperlyte CR Potassium acetate (1.96 g/20mL) + Calcium chloride dihydrate (0.37 g/20mL) + Magnesium chloride hexahydrate (0.51 g/20mL) + Sodium acetate trihydrate (0.68 g/20mL) + Sodium chloride (1.17 g/20mL) Injection, solution, concentrate Intravenous B. Braun Medical Inc. 2012-04-12 Not applicable US Nutrilyte Potassium acetate (34.5 mg/1mL) + Calcium acetate (22 mg/1mL) + Sodium gluconate (55 mg/1mL) + Magnesium acetate (43 mg/1mL) + Potassium chloride (125 mg/1mL) + Sodium acetate trihydrate (135 mg/1mL) Injection, solution, concentrate Intravenous American Regent 1990-09-30 2013-05-08 US Nutrilyte II Potassium acetate (98 mg/1mL) + Calcium chloride dihydrate (16.55 mg/1mL) + Magnesium chloride hexahydrate (25.5 mg/1mL) + Sodium acetate trihydrate (64.6 mg/1mL) + Sodium chloride (74.5 mg/1mL) Injection, solution, concentrate Intravenous American Regent 1990-10-01 2014-01-01 US Nutrilyte II Potassium acetate (98 mg/1mL) + Calcium chloride dihydrate (16.55 mg/1mL) + Magnesium chloride hexahydrate (25.5 mg/1mL) + Sodium acetate trihydrate (64.6 mg/1mL) + Sodium chloride (74.5 mg/1mL) Injection, solution, concentrate Intravenous American Regent 1990-10-01 2014-01-01 US Potassium Acetate Potassium acetate (392 mg/1mL) Injection, solution, concentrate Intravenous American Regent 1990-09-30 2014-07-01 US Potassium Acetate Potassium acetate (196 mg/1mL) Injection, solution Intravenous American Regent 1990-09-30 2012-11-29 US
Categories
- ATC Codes
- B05XA17 — Potassium acetate
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as acetate salts. These are organic compounds containing acetic acid as its acid component.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Carboxylic acids and derivatives
- Sub Class
- Carboxylic acid derivatives
- Direct Parent
- Acetate salts
- Alternative Parents
- Monocarboxylic acids and derivatives / Carboxylic acids / Organic potassium salts / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
- Substituents
- Acetate salt / Aliphatic acyclic compound / Carbonyl group / Carboxylic acid / Hydrocarbon derivative / Monocarboxylic acid or derivatives / Organic alkali metal salt / Organic oxide / Organic oxygen compound / Organic potassium salt
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- potassium salt (CHEBI:32029)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- M911911U02
- CAS number
- 127-08-2
- InChI Key
- SCVFZCLFOSHCOH-UHFFFAOYSA-M
- InChI
- InChI=1S/C2H4O2.K/c1-2(3)4;/h1H3,(H,3,4);/q;+1/p-1
- IUPAC Name
- potassium acetate
- SMILES
- [K+].CC([O-])=O
References
- General References
- Not Available
- External Links
- KEGG Compound
- C12554
- ChemSpider
- 29104
- ChEBI
- 32029
- ChEMBL
- CHEMBL1201058
- Wikipedia
- Potassium_acetate
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Completed Treatment Critically Ill Patients 1 3 Completed Treatment Parenteral Nutrition for Patients With Proven Insufficient Enteral Resorption 1 2 Completed Treatment Acute Heart Failure (AHF) / Decompensated Heart Failure / Heart Failure 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Solution Intravenous 10.50 g/1000ml Injection Intravenous 0.5 g/l Injection Intravenous 0.25 g/1000ml Solution Intravenous Injection Intravenous 2.45 g/5ml Emulsion Intravenous 0.468 g Injection, emulsion Parenteral Emulsion Intravenous 0.466 g Emulsion Parenteral Emulsion Intravenous Injection, emulsion Intravenous 4.656 g/1000ml Injection, emulsion Intravenous 6.792 g/1000ml Injection, solution, concentrate Intravenous Injection, emulsion Intravenous Injection Intravenous Liquid Intravenous Injection, solution Intravenous Injection, solution Parenteral Injection, solution, concentrate Intravenous Injection, solution, concentrate Intravenous 3 MEQ/ML Injection Intravenous 100 meq/50mL Injection Intravenous 200 meq/100mL Injection, solution Intravenous 196 mg/1mL Injection, solution, concentrate Intravenous 196.3 mg/1mL Injection, solution, concentrate Intravenous 3.93 g/20mL Injection, solution, concentrate Intravenous 392 mg/1mL Solution Intravenous 2 mEq / mL Liquid Intravenous 392 mg / mL Solution Intravenous 392 mg / mL Liquid Intravenous 39.2 % w/v - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 342.0 mg/mL ALOGPS logP -0.27 ALOGPS logP -0.22 Chemaxon logS 0.54 ALOGPS pKa (Strongest Acidic) 4.54 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 2 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 40.13 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 23.48 m3·mol-1 Chemaxon Polarizability 4.96 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Steroid hormone binding
- Specific Function
- This is the catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of sodium and potassium ions across the plasma membrane. This action creates th...
- Gene Name
- ATP1A1
- Uniprot ID
- P05023
- Uniprot Name
- Sodium/potassium-transporting ATPase subunit alpha-1
- Molecular Weight
- 112895.01 Da
References
- Silva E, Gomes P, Soares-da-Silva P: Overexpression of Na(+)/K (+)-ATPase parallels the increase in sodium transport and potassium recycling in an in vitro model of proximal tubule cellular ageing. J Membr Biol. 2006;212(3):163-75. Epub 2007 Feb 28. [Article]
- Li C, Geering K, Horisberger JD: The third sodium binding site of Na,K-ATPase is functionally linked to acidic pH-activated inward current. J Membr Biol. 2006;213(1):1-9. Epub 2007 Mar 8. [Article]
- Stanely Mainzen Prince P, Karthick M: Preventive effect of rutin on lipids, lipoproteins, and ATPases in normal and isoproterenol-induced myocardial infarction in rats. J Biochem Mol Toxicol. 2007;21(1):1-6. [Article]
- Simon WA, Herrmann M, Klein T, Shin JM, Huber R, Senn-Bilfinger J, Postius S: Soraprazan: setting new standards in inhibition of gastric acid secretion. J Pharmacol Exp Ther. 2007 Jun;321(3):866-74. Epub 2007 Mar 16. [Article]
- Iannello S, Milazzo P, Belfiore F: Animal and human tissue Na,K-ATPase in normal and insulin-resistant states: regulation, behaviour and interpretative hypothesis on NEFA effects. Obes Rev. 2007 May;8(3):231-51. [Article]
Drug created at July 11, 2018 16:28 / Updated at September 30, 2023 15:27